AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01542450 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin detemir
Description: Single dose of 0.3 U/kg administered subcutaneously (s.c. under the skin) in each treatment period separated by a washout period of 4-28 days
Study NCT01373151 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab Placebo
Description: Injection, Subcutaneous, 0 mg, Every 2 weeks, 48 weeks
Study NCT01542450 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin detemir
Description: Single dose of 0.3 U/kg administered subcutaneously (s.c. under the skin) in each treatment period separated by a washout period of 4-28 days
Study NCT01542450 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin NPH
Description: Single dose of 0.3 U/kg administered subcutaneously (s.c. under the skin) in each treatment period separated by a washout period of 4-28 days
Study NCT01542450 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin NPH
Description: Single dose of 0.3 U/kg administered subcutaneously (s.c. under the skin) in each treatment period separated by a washout period of 4-28 days
Study NCT03481452 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: psychotherapy
Description: NBO is an infant-focused, family relationship-based intervention measure, which aims to exhibit to parents infants' surprised ability, understand infants' strength and aspects needed to be improved, strength parents' parenting confidence, and promote sound development of infant-mother relationship.
Study NCT00742911 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Disulfiram
Description: Patients will take a pill of disulfiram at a fixed dose of 250 mg with their evening meal. This dose of disulfiram used to treat alcoholism. We will start by administering 2 mg of copper as copper gluconate along with 250 mg disulfiram.~Patients must not consume beverages containing alcohol while taking disulfiram.
Study NCT00742911 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copper Gluconate
Description: Commercially available. Copper gluconate has long been manufactured and sold as a food supplement. Copper gluconate should be taken separately from disulfiram, and if possible with breakfast.~Copper gluconate should not be administered to individuals with Wilson's disease or a family history of Wilson's disease.~Patients will receive 2 mg, 4mg, 6mg or 8mg daily
Study NCT00871156 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chloroquine, Tafenoquine
Description: Chloroquine and Tafenoquine
Study NCT00871156 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Chloroquine, Tafenoquine
Description: Chloroquine and Tafenoquine
Study NCT00871156 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03720678 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etrumadenant
Description: Etrumadenant is an A2aR and A2bR antagonist.
Study NCT03720678 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFOX
Description: Oxaliplatin, Leucovorin and 5-fluorouracil given as part of standard mFOLFOX chemotherapy regimen
Study NCT01373151 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab
Description: Injection, Subcutaneous, 40 mg, Every 2 weeks, 48 weeks
Study NCT01363544 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neurofeedback
Description: 30 sessions of theta/beta neurofeedback within 10 weeks.
Study NCT01363544 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: 30 sessions of individual sports training during 10 weeks.
Study NCT01363544 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methylphenidate
Description: The medication treatment is based on the MTA study and includes methylphenidate dosages of 5, 10, 15 (only for children with a weight below 25 kg) and 20 mg (only for children with a weight above 25 kg. The optimum dose will be determined by a double-blind placebo-controlled trial.
Study NCT03440060 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: procalcitonin
Description: procalcitonin value will be obtained within 24 hours after ICU admission in both groups and will be taken into account in the procalcitonin group only
Study NCT03243682 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bidirectional Shock Wave Lithotripsy
Description: the alternating bidirectional (under and over table) approach during SWL for renal and upper lumbar ureteric stones
Study NCT02395068 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nimotuzumab
Description: single dose of nimotuzumab (100、200、400、600mg), with 3 weeks observation；Set 4 dose groups for Nimotuzumab, namely 100,200,400,600mg. Each group administered once a week for 6 weeks；600mg, administered once every 2 weeks for 8 weeks.
Study NCT02395068 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan
Description: Single-dose PK：1 week after nimotuzumb administration, irinotecan (CPT-11) will be given at a dose of 180 mg/m2 once every 2 weeks, 2 weeks a cycle.~Bioweekly fixed dose PK：Nimotuzumab combined with irinotecan (180mg/m2), administering once every 2 weeks and considering 2 weeks as a period. If chemotherapy and Nimotuzumab are administered in the same day, chemotherapy should be infused after Nimotuzumab for at least 1h
Study NCT03243682 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Shock Wave Lithotripsy
Description: the standard unidirectional approach during SWL for renal and upper lumbar ureteric stones
Study NCT04482959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbetocin
Description: (1-deamino-1-monocarba-(0-2-methyltyrosine)-oxytocin) is a long-acting synthetic agonist analogue of the human oxytocin
Study NCT04482959 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium chloride 0.9%
Description: Physiological solution will be used as placebo
Study NCT03767829 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALN-AAT02
Description: ALN-AAT02 will be administered subcutaneously (SC) at dose levels planned for Part A.
Study NCT03767829 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sterile normal saline (0.9% NaCl) matching volume of ALN-AAT02 doses will be administered SC.
Study NCT03767829 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALN-AAT02
Description: ALN-AAT02 will be administered subcutaneously (SC). Part B dose levels to be determined upon review of data from Part A.
Study NCT02097173 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Methotrexate
Study NCT04801277 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Electroacupuncture on acupoints vs sham points
Description: Randomized double blinded clinical trial
Study NCT04801277 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Electroacupuncture on acupoints vs sham points
Description: Randomized double blinded clinical trial
Study NCT04624087 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: food-specific go/no-go computerized training
Description: Participants will perform the computerized food specific go/no-go training a designated number of times over a four week duration (frequency varies by group). Each training session will last approximately 10 minutes and occur on different days of the week.
Study NCT04624087 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: nonfood-specific go/no-go computerized training
Description: Participants will perform the computerized general go/no-go training 1 time per week over a four week duration. Each training session will last approximately 10 minutes and occur on different days of the week.
Study NCT04846777 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mindfulness ecological momentary intervention
Description: Access to a smartphone-delivered mindfulness ecological momentary intervention with the Personal Analytics Companion (PACO) app that regularly prompts participants to practice various mindfulness skills at 5 preset times each day.
Study NCT04846777 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Self-monitoring placebo
Description: Access to a smartphone-delivered self-monitoring placebo with the PACO app that regularly prompts participants to practice self-monitoring at 5 preset times each day.
Study NCT04548102 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fetal movement count
Description: Pregnant women in the study group received verbal information regarding normal fetal movements (i.e. description of the changing pattern of movement as the fetus develops, normal sleep/wake cycles, and factors which may modify the mother's perception of movements such as maternal weight and placental position), and its importance to be followed during the third trimester. A chart for fetal movements counting provided and to ensure proper performance of this task, women telephoned once a week. They also asked to show the fetal movements chart to the researcher and the health care providers in each visit. Women followed according to her antenatal visits schedule till delivery.
Study NCT03583775 — intervention group
Intervention type: OTHER
Intervention: Cardiovascular Magnetic Resonance Imaging
Description: Cardiovascular Magnetic Resonance Imaging or MRI exam from children's with congenital heart disease
Study NCT00586612 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Menitorix™
Description: Intramuscular injection, 3 doses in the primary study and 1 dose in the Booster study.
Study NCT00586612 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Menitorix™
Description: Intramuscular injection, 3 doses in the primary study and 1 dose in the Booster study.
Study NCT00586612 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Infanrix™ penta
Description: Intramuscular injection, 3 doses in the primary study
Study NCT00586612 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infanrix™ penta
Description: Intramuscular injection, 3 doses in the primary study
Study NCT00586612 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevenar™
Description: Intramuscular injection, 3 doses in the primary study and 1 dose in the Booster study.
Study NCT00586612 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prevenar™
Description: Intramuscular injection, 3 doses in the primary study and 1 dose in the Booster study.
Study NCT00586612 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Infanrix™ IPV
Description: Intramuscular injection, 1 dose in the Booster study.
Study NCT00586612 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infanrix™ IPV
Description: Intramuscular injection, 1 dose in the Booster study.
Study NCT02862522 — intervention group
Intervention type: OTHER
Intervention: Questionnaire of overall health
Description: The standardized questionnaire was used to assess occurrence of major adverse cardiovascular events including stroke, re-hospitalization, myocardial infarction or death. Responses were verified by medical record review conducted by an investigator blinded to the results of the standardized questionnaire.
Study NCT01879553 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TIV
Description: Trivalent Influenza Virus Vaccine (surface antigen, inactivated, egg-derived)
Study NCT00847080 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin phosphate
Description: Sitagliptin phosphate 100 mg per day per 2 weeks
Study NCT00847080 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 1 tablet per day per 2 weeks
Study NCT04322903 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Passport to Freedom (P2F)
Description: During the P2F sessions, the women learn to understand and process the impact of multiple traumas on women's lives and health and learn specific strategies to overcome the symptoms of trauma and everyday stress. Each session will begin and end with a mindfulness exercise to provide different strategies the women can use when these women are in a stressful situation. At the end of each session, the participants will complete a session evaluation. The women will also have a home visit or telephone call with a community health navigator who will conduct a social determinant of health screenings assessment to determine what identified social barriers these women may have. The community health navigator will help with linking the participant to a community agency that addresses the identified problem. Four weeks after the completion of the program, the women will be contacted for a follow-up interview to learn the effectiveness of the program sessions.
Study NCT02753543 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chidamide
Study NCT04337853 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intraoral stent
Description: Radiotherapy with intraoral stent
Study NCT04337853 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No intraoral stent
Description: Radiotherapy without intraoral stent
Study NCT03294694 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib
Description: Each treatment cycle lasts 28 days. Ribociclib, 1 time per day by mouth for 21 days, followed by 1-week of rest (28-day cycle)
Study NCT03294694 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PDR001
Description: Each treatment cycle lasts 28 days. (PDR001) will be administered once every 28 days (by intravenous infusion) over about 30 minutes (or up to 2 hours, if necessary) for the first infusion and over about 30 minutes for all following infusions.
Study NCT03294694 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Each treatment cycle lasts 28 days. Fulvestrant will be administered during Cycle 1 on days 1 and 15, and then on day 1 of each 28-day cycle thereafter.
Study NCT03787836 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Maintained Exercise
Description: Complete 28 weeks of aerobic exercise, with one week (following week 16) for testing.~Week 1 - 16 Intensity: 4.5 metabolic equivalents (METs).~Duration:~Week 1: 80 minutes Week 2: 100 minutes Week 3: 120 minutes Week 4: 135 minutes Week 5 - 16: 150 minutes/week~Week 17: Physiological Testing~Week 18 - 29 Intensity: 4.5 METs Duration: 150 minutes/week~All exercise must be completed across a minimum of two sessions per week. Sub-maximal exercise tests will be completed every 4 weeks to adjust intensity.
Study NCT03787836 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Increased Intensity
Description: Complete 28 weeks of aerobic exercise, with one week (following week 16) for testing.~Week 1 - 16 Intensity: 4.5 metabolic equivalents (METs).~Duration:~Week 1: 80 minutes Week 2: 100 minutes Week 3: 120 minutes Week 4: 135 minutes Week 5 - 16: 150 minutes/week~Week 17: Physiological Testing~Week 18 - 29 Intensity: 6.0 METs Duration: 150 minutes/week~All exercise must be completed across a minimum of two sessions per week. Sub-maximal exercise tests will be completed every 4 weeks to adjust intensity.
Study NCT01334424 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: propofol
Description: 2-2.5 mg/kg for induction plus or not plus 2 mg/kg.h for maintenance
Study NCT01334424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propofol
Description: 2-2.5 mg/kg for induction plus or not plus 2 mg/kg.h for maintenance
Study NCT03350932 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sensory imagination about foods
Description: In both groups, children will be presented with pictures of items. In the control group, the pictures will represent landscapes at different seasons. In the experimental group, the pictures will represent a variety of foods. In the experimental group, based on the pictures representing a variety of foods, children will have to perform a food sensory imagination task before choosing the portion size of a food.
Study NCT00955175 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: hypofractionated radiation therapy
Description: Given 5 days a week for 20, 22, or 24 fractions
Study NCT00652470 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic Third Ventriculostomy
Description: A standard frontal burr hole will be made and an endoscopic camera used to visualize the floor of the third ventricle. A ventriculostomy will be created in the floor of the third using the surgeon's own preferred method of perforation.
Study NCT00652470 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CSF Shunt Insertion
Description: The procedure involves creating a burr hole in the frontal or occipital regions and cannulating the ventricle with a silastic catheter. This is then attached to a valve mechanism and distal silastic tubing which runs subcutaneously in the peritoneal cavity.
Study NCT00649636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoxetine Capsules 40 mg
Description: 40mg, single dose fasting
Study NCT00649636 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prozac Pulvules 40 mg
Description: 40mg, single dose fasting
Study NCT00126503 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV
Study NCT00126503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib Tosylate
Description: Given PO
Study NCT00126503 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT00126503 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03283735 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Elderly Enablement
Description: The information given in this group will result from the knowledge obtained in previous phase of the study in the shape of small leaflets and other information materials to be made according to the best practice, to be given and remembered at scheduled times to the intervention group
Study NCT02383524 — intervention group
Intervention type: PROCEDURE
Intervention: Lumbar Radiofrequency Medial Branch Neurolysis
Description: Numerous studies have concluded that facet joint pain can be accurately diagnosed if a significant (but temporary) reduction in pain is achieved with a procedure called a Medial Branch Block (MBB). The clinician delivers a targeted injection of local anesthetic to the joint itself, or in close proximity to the medial branch of the posterior rami of the dorsal root. A significant decrease in pain confirms that the pain originates from the facet joint. If or when the pain returns after successful MBB treatment the patient may be considered for radiofrequency denervation (neurotomy) which selectively disrupts the joint's nerve supply and provides longer-term sustained relief
Study NCT01954849 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Probiotic formulation
Study NCT01954849 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic formulation
Study NCT04611100 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ELRA endoluminal radiofrequency ablation electrode (Taewoong, Seoul, Korea)
Description: Intraductal radiofrequency ablation using ELRA endoluminal radiofrequency ablation electrode (Taewoong, Seoul, Korea) 10W 2 minutes at the obstructed bile duct before placing uncover self-expandable biliary metal stent
Study NCT04321577 — intervention group
Intervention type: PROCEDURE
Intervention: Radical surgery
Description: Radical surgery is proposed to participants with pT1b, pT2 or pT3 tumors in the cholecystectomy specimen without evidence of disseminated disease with staging imaging techniques. A resection of the gallbladder bed or an anatomic resection of the hepatic segments IVb/V is performed. A lymphadenectomy of the hepatic hilum is associated in all cases. Common bile duct resection is performed in patients with involvement of the cystic margin.
Study NCT03825549 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual audit feedback
Description: Practice sites randomly assigned to have individual audit feedback will be sent information by email to each clinician at the site each month for the duration of the intervention period. The email will inform the clinician that the health system is doing monthly audits and provide them the number of patients in the last month for whom they prescribed 30 opioid pills per prescription or higher.
Study NCT03825549 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer comparison feedback
Description: Practice sites randomly assigned to have peer comparison feedback will be sent information by email to each clinician at the site each month for the duration of the intervention period. Data on the mean number of opioid pills per prescription and the proportion of visits with an opioid prescription will be delivered using a 3-month rolling average as follows: a) If clinician is above median: informed how their data compares to the median; b) If clinician is below median but above 10th percentile: informed how their data compares to the 10th percentile; c) If clinician is 10th percentile or below: informed of their data and commended for being a low prescriber.
Study NCT02412371 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Administered via intravenous infusion on Day 1 of each treatment week (concurrent CRT) / cycle (consolidation)
Study NCT02412371 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Administered via intravenous infusion on Day 1 of each treatment week (concurrent CRT) / cycle (consolidation)
Study NCT02412371 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for Veliparib
Description: Capsule for oral administration
Study NCT02412371 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Veliparib
Description: Capsule for oral administration